Advanced cannabinoid scientific platform at MaRS
Discovery District Toronto
Who We Are
Global commercialization strategy with diversified & high margin income streams across 12+ countries.
Comprehensive commercial portfolio
Consumer, medical cannabis and cannabinoid supply chain
Multinational sales with international footprint
USA, Canada, Europe and LATAM
Revenue generation and scale up phase
3 consecutive Q-Q growth of minimum 30%
Proven scientific platform, including R&D, pre-clinical and clinical infrastructure in Canada
Cannabinoid drug development pipeline
30+ advanced commercial SKUs + pharmaceutical pipeline
World-renowned collaborations
with leading Canadian academic and clinical institutions
JLABS @ Toronto, Johnson & Johnson Innovation Centre
R&D headquarters in the MaRS Discovery District
Established and environmentally sustainable low-cost vertical integration in Colombia
Two Colombian majority-owned subsidiaries
cultivation footprint of 480,000 sq feet with industrial extraction capacity
World-renowned collaborations
with leading Canadian academic and clinical institutions
Organic and sustainable cultivation
ranked highest amongst global cannabis companies in a corporate sustainability assessment – issued by S&P Global in 2020
Our Portfolio
The Company actively collaborates with leading Canadian academic and medical institutions.
Avicanna has established an industry-leading scientific platform including advanced R&D and clinical development which has led to the commercialization of over twenty products across four main market segments:
Commercial Stage
Medical Cannabis and Wellness Products
Commercial Stage
CBD Dermacosmetics Consumer Retail Products*
In Development and Registration Stage
Pharmaceutical Pipeline
Commercial Stage
Cannabinoid API & Seeds
Industry Leading Scientific Platform
Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products
Established Research & Development Platform
Setting the Standard in the Cannabinoid Industry with Advanced and Evidence Based Product
R&D headquarters at JLABS @ Toronto, Johnson & Johnson Innovation Centre in the MaRS Discovery District Drug development pipeline, including sustained release tablets, transdermal patches and nano participle formulations
30+
Proprietary Commercial Products
10+
Scientists
7+
Canadian Government research grants awarded since 2020
8+
Pending Patents
4+
4 Health Canada issued cannabis research licenses issued to Avicanna or institutional collaborators over the
past 4 years
World-Class Collaborations
R&D and Clinical Partnerships Over the Past 4 Years
World-Class Collaborations
R&D collaborations with world-class academic and clinical institutes
Avicanna counts with collaborations with world-class academic and clinical institutes Including 4 Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators.
MaRS Discovery
District
University Health
Network
Hospital of
Sick Children
University of
Guelph
JLABS @ Toronto
University of
Toronto
Sunnybrook Health
Science Centre
Clinical Development
Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products
08.08.2021
Products & Pipeline
Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products
